*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2014 | Physiology and therapeutic potential of the thymic peptide thymulin Current pharmaceutical design · preclinical | PMID 24588820 |
| 2011 | Neonatal thymulin gene therapy in nude mice: Effects on the morphology of the pituitary corticotrope population Histology and histopathology · preclinical | PMID 21360440 |
| 2010 | Immunomodulatory role of thymulin in lung diseases Expert opinion on therapeutic targets · preclinical | PMID 20055713 |
| 2004 | Thymulin and the neuroendocrine system Peptides · preclinical | PMID 15003367 |
| 2002 | The effects of thymulin on macrophage responsiveness to interferon-gamma Developmental and comparative immunology · preclinical | PMID 11687267 |
| 1998 | Thymic endocrinology Annals of the New York Academy of Sciences · preclinical | PMID 9629262 |
| 1998 | Thymulin stimulates prolactin and thyrotropin release in an age-related manner Mechanisms of ageing and development · preclinical | PMID 9818729 |
| 1995 | Zinc: an overview Nutrition (Burbank, Los Angeles County, Calif.) · preclinical | PMID 7749260 |
| 1992 | Thymulin and its role in immunomodulation Journal of autoimmunity · preclinical | PMID 1418292 |
| 1992 | Thymic endocrinology International journal of immunopharmacology · preclinical | PMID 1618588 |
| 1989 | Thymulin, a zinc-dependent hormone Medical oncology and tumor pharmacotherapy · preclinical | PMID 2657247 |
| 1985 | Thymulin Methods in enzymology · preclinical | PMID 3878920 |
Thymulin (Thymulin (zinc-dependent thymic nonapeptide)). Zinc-dependent thymic hormone (nonapeptide) involved in T-cell differentiation and immune regulation; has neuroendocrine and anti-inflammatory/analgesic roles in preclinical models.
Commonly discussed uses: immune-modulation research, neuroinflammation research (preclinical). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Zinc-dependent thymic hormone (nonapeptide) involved in T-cell differentiation and immune regulation; has neuroendocrine and anti-inflammatory/analgesic roles in preclinical models.
Reported considerations: limited human safety data. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical research peptide. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose, high research-defined. Administration: subcutaneous (research), intranasal (research). Half-life: short; zinc-dependent activity.
Australian status: Not ARTG-registered; research. Preclinical research peptide. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: frozen aliquots.
Commonly discussed combinations (anecdotal for unapproved compounds): research peptide; no protocols. Stacking increases interaction/safety uncertainty.